Innovent Biologics (IVBXF) Stock Forecast & Price Target

Q: What is IVBXF’s average 12-month price target, according to analysts?

Based on analyst ratings, Innovent Biologics’s 12-month average price target is 14.92.

Q: What is IVBXF’s upside potential, based on the analysts’ average price target?

Innovent Biologics has 42.50% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is IVBXF a Buy, Sell or Hold?

Innovent Biologics has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

Q: What is Innovent Biologics’s price target?

The average price target for Innovent Biologics is 14.92. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $17.66 ,the lowest forecast is $13.49. The average price target represents 42.50% Increase from the current price of $10.47.

Q: What do analysts say about Innovent Biologics?

Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

Q: How can I buy shares of IVBXF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

41 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IVBXF Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Innovent

Biologics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IVBXF Stock 12 Month Forecast

Average Price Target

$14.92

▲(42.50% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is $14.92 with a high forecast of $17.66 and a low forecast of $13.49. The average price target represents a 42.50% change from the last price of $10.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","18":"$18","6.75":"$6.75","10.5":"$10.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.6582358,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.494285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.75,10.5,14.25,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,12.555248907692308,12.980497815384616,13.405746723076923,13.83099563076923,14.256244538461539,14.681493446153846,15.106742353846155,15.531991261538462,15.957240169230769,16.38248907692308,16.807737984615386,17.232986892307693,{"y":17.6582358,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,12.344615384615386,12.55923076923077,12.773846153846154,12.98846153846154,13.203076923076924,13.417692307692308,13.632307692307693,13.846923076923076,14.061538461538461,14.276153846153846,14.490769230769232,14.705384615384615,{"y":14.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.13,12.234945000000002,12.33989,12.444835000000001,12.54978,12.654725000000001,12.75967,12.864615,12.96956,13.074505,13.17945,13.284395,13.38934,{"y":13.494285,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.99,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.66

Average Price Target$14.92

Lowest Price Target$13.49

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rebecca Liang

Bernstein

$14.39→$14.78

Buy

41.16%

Upside

Reiterated

12/12/25

Innovent Biologics (IVBXF) Gets a Buy from Bernstein

Matthew Yan

CLSA

$15.43

Buy

47.42%

Upside

Reiterated

12/08/25

CLSA Keeps Their Buy Rating on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

$17.66

Buy

68.66%

Upside

Reiterated

12/08/25

Innovent Biologics (IVBXF) Gets a Buy from UBS

Unknown Analyst

UBS

Not Ranked

UBS

$17.66

Buy

68.66%

Upside

Reiterated

11/28/25

Unknown Analyst

Zhongtai Securities

Not Ranked

Zhongtai Securities

$14.99

Buy

43.12%

Upside

Reiterated

11/12/25

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

$16.45

Buy

57.12%

Upside

Reiterated

11/06/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

$14.78

Buy

41.16%

Upside

Reiterated

10/27/25

Unknown Analyst

CICC

Not Ranked

CICC

$15.2

Buy

45.21%

Upside

Reiterated

10/24/25

Jill Wu

CMB International Securities

$14.07→$14.22

Buy

35.78%

Upside

Reiterated

10/23/25

Innovent Biologics and Takeda Partnership Fuels Global Expansion and Strengthens Buy Rating

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$13.49

Buy

28.89%

Upside

Reiterated

10/23/25

BOCOM International Holdings Company Remains a Buy on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

$15.43→$17.66

Buy

68.66%

Upside

Reiterated

10/22/25

Yang Huang

J.P. Morgan

$14.65→$14.14

Buy

35.02%

Upside

Reiterated

10/22/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

$13.74→$14.52

Buy

38.71%

Upside

Reiterated

10/22/25

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$13.49

Buy

28.89%

Upside

Reiterated

10/08/25

Unknown Analyst

HSBC

Not Ranked

HSBC

$14.78

Buy

41.16%

Upside

Reiterated

09/30/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rebecca Liang

Bernstein

$14.39→$14.78

Buy

41.16%

Upside

Reiterated

12/12/25

Innovent Biologics (IVBXF) Gets a Buy from Bernstein

Matthew Yan

CLSA

$15.43

Buy

47.42%

Upside

Reiterated

12/08/25

CLSA Keeps Their Buy Rating on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

$17.66

Buy

68.66%

Upside

Reiterated

12/08/25

Innovent Biologics (IVBXF) Gets a Buy from UBS

Unknown Analyst

UBS

Not Ranked

UBS

$17.66

Buy

68.66%

Upside

Reiterated

11/28/25

Unknown Analyst

Zhongtai Securities

Not Ranked

Zhongtai Securities

$14.99

Buy

43.12%

Upside

Reiterated

11/12/25

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

$16.45

Buy

57.12%

Upside

Reiterated

11/06/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

$14.78

Buy

41.16%

Upside

Reiterated

10/27/25

Unknown Analyst

CICC

Not Ranked

CICC

$15.2

Buy

45.21%

Upside

Reiterated

10/24/25

Jill Wu

CMB International Securities

$14.07→$14.22

Buy

35.78%

Upside

Reiterated

10/23/25

Innovent Biologics and Takeda Partnership Fuels Global Expansion and Strengthens Buy Rating

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

$13.49

Buy

28.89%

Upside

Reiterated

10/23/25

BOCOM International Holdings Company Remains a Buy on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

$15.43→$17.66

Buy

68.66%

Upside

Reiterated

10/22/25

Yang Huang

J.P. Morgan

$14.65→$14.14

Buy

35.02%

Upside

Reiterated

10/22/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

$13.74→$14.52

Buy

38.71%

Upside

Reiterated

10/22/25

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$13.49

Buy

28.89%

Upside

Reiterated

10/08/25

Unknown Analyst

HSBC

Not Ranked

HSBC

$14.78

Buy

41.16%

Upside

Reiterated

09/30/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innovent Biologics

1 Month

xxx

Success Rate

8/11 ratings generated profit

Average Return

+9.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +9.40% per trade.

3 Months

xxx

Success Rate

5/6 ratings generated profit

Average Return

+28.12%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +28.12% per trade.

1 Year

Rebecca LiangBernstein

Success Rate

7/10 ratings generated profit

Average Return

+37.43%

reiterated a buy rating 11 days ago

Copying Rebecca Liang's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +37.43% per trade.

2 Years

xxx

Success Rate

12/14 ratings generated profit

Average Return

+68.10%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +68.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IVBXF Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IVBXF has received 15 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. IVBXF average Analyst price target in the past 3 months is 14.92.

Each month's total comprises the sum of three months' worth of ratings.

IVBXF Financial Forecast

IVBXF Earnings Forecast

Next quarter’s earnings estimate for IVBXF is <$0.01 with a range of <$0.01 to <$0.01. The previous quarter’s EPS was $0.07. IVBXF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IVBXF has Performed in-line its overall industry.

IVBXF Sales Forecast

Next quarter’s sales forecast for IVBXF is $934.79M with a range of $914.70M to $954.88M. The previous quarter’s sales results were $822.01M. IVBXF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IVBXF has Performed in-line its overall industry.

IVBXF Stock Forecast FAQ

What is IVBXF’s average 12-month price target, according to analysts?

Based on analyst ratings, Innovent Biologics’s 12-month average price target is 14.92.

What is IVBXF’s upside potential, based on the analysts’ average price target?

Innovent Biologics has 42.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IVBXF a Buy, Sell or Hold?

Innovent Biologics has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Innovent Biologics’s price target?

The average price target for Innovent Biologics is 14.92. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.66 ,the lowest forecast is $13.49. The average price target represents 42.50% Increase from the current price of $10.47.

What do analysts say about Innovent Biologics?

Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of IVBXF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Innovent Biologics (IVBXF) Stock Forecast & Price Target

IVBXF Analyst Ratings

IVBXF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Innovent Biologics

IVBXF Analyst Recommendation Trends

IVBXF Financial Forecast

IVBXF Earnings Forecast

IVBXF Sales Forecast

IVBXF Stock Forecast FAQ

Detailed List of Analyst Forecasts